Mark Talamonti to Tumor Necrosis Factor-alpha
This is a "connection" page, showing publications Mark Talamonti has written about Tumor Necrosis Factor-alpha.
Connection Strength
0.016
-
Efficacy of efalizumab in psoriasis patients previously treated with tumour necrosis factor blockers. Dermatology. 2009; 219(1):48-53.
Score: 0.016
Connection Strength
The connection strength for concepts is the sum of the scores for each matching publication.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.